Please login to the form below

Not currently logged in
Email:
Password:

Janssen

This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

UPDATE: US pauses rollout of J&J’s COVID-19 vaccine amid reports of rare blood clots

These reports point to a ‘safety signal’, but it is currently not clear whether there is a causal association between vaccination with COVID-19 Vaccine Janssen and these conditions,' said the

Latest news

More from news
Approximately 141 fully matching, plus 402 partially matching documents found.

Latest Intelligence

  • Unlocking the potential of precision medicine in oncology Unlocking the potential of precision medicine in oncology

    Joaquín Casariego García-Lubén talks to PME about how Janssen is driven by the premise of providing personalised treatment solutions in cancer care. ... Joaquín Casariego García-Lubén is EMEA Therapeutic Area Lead Oncology, The Janssen

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Will biosimilars ever catch on in the US? Will biosimilars ever catch on in the US?

    Pfizer also cited a Janssen brochure that allegedly implied the biosimilar Inflectra is not interchangeable with Remicade and may pose a safety risk.

  • The first, my last, my everything The first, my last, my everything

    It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Katrin Haeverans, EPAD LCS and POC platform support, Janssen said: “EPAD has been built to facilitate proof-of-concept trials. ... Sir Simon Lovestone. After 18 years in old age psychiatry and dementia research in academia, Sir Simon Lovestone joined

More from intelligence
Approximately 5 fully matching, plus 52 partially matching documents found.

Latest appointments

More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 5 fully matching, plus 30 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics